Experience of using prolgolimab in real clinical practice


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Melanoma of the skin is one of the most aggressive malignant neoplasms. Approaches to the treatment of metastatic skin melanoma have been dynamically developing over the past decade. The first original IgG1 anti-PD-lmonoclonal antibody containing the Fc-silencing ‘LALA’ mutation has been developed in Russia. This article demonstrates our own experience of using the domestic PD-1 inhibitor prolgolimab in clinical practice.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. Imyanitov

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. Malygin

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Yurlov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Semenova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. Novik

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

G. Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. Zinoviev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. Ebert

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. Artemieva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. Baldueva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

Әдебиет тізімі

  1. Tjulandin S., Fedyanin M., Semiglazova T., et al. BCD-100 - first Russian PD-1 inhibitor. J Mod Oncol. 2017;19:13-20.
  2. Tjulandin S., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030.
  3. Rozeman E.A., et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021; 27(2):256-63. doi: 10.1038/s41591-020- 01211-7
  4. Blank C.U., Reijers I.L.M., Pennington T., et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38;15S. URL: https://meetinglibrary.asco.org/record/185836/ abstract
  5. Krishnamoorthy M., Lenehan J.G., Vareki S.M. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges, JNCI: J Nation Cancer Inst. 2021, djaa216. doi: 10.1093/jnci/djaa216. 7-y
  6. Huang A.C., et al.Asingledose ofneoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019;25(3):454-61. doi: 10.1038/s41591-019-0357-y

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>